Durheim Michael T, Judy Jennifer, Bender Shaun, Neely Megan L, Baumer Dorothy, Robinson Scott B, Conoscenti Craig S, Leonard Thomas B, Lazarus Howard M, Palmer Scott M
Duke Clinical Research Institute.
Duke University Medical Center, Durham, North Carolina, USA.
Medicine (Baltimore). 2020 Nov 20;99(47):e23143. doi: 10.1097/MD.0000000000023143.
Hospitalizations are common in patients with idiopathic pulmonary fibrosis (IPF) and are associated with high mortality. We used data from the Premier Healthcare Database to determine in-hospital mortality rates and the factors associated with in-hospital mortality in patients with IPF in the era of approved antifibrotic drugs.The Premier Healthcare Database is a detailed and broadly representative database of hospital admissions and discharges in the US. Patients with IPF who were hospitalized between 1 January 2015 and 28 February 2018 were identified using a diagnostic algorithm comprising International Classification of Diseases -9 and International Classification of Diseases -10 diagnostic codes and billing data. Associations between patient-, hospital- and treatment-related factors and a composite outcome of death during the index visit, lung transplant during the index visit but >1 day after admission, or death during a readmission within 90 days of the index visit were analyzed using logistic regression.The cohort comprised 9667 hospitalized patients with IPF. In total, 1414 patients (14.6%) met the composite outcome: 1036 (10.7%) died during the index visit, 371 (3.8%) died during a readmission within 90 days; 7 (0.1%) underwent lung transplant >1 day after admission. Factors significantly associated with a higher risk of the composite outcome included mechanical ventilation (odds ratio 6.41 [95% CI: 5.24, 7.84]), admission to the intensive care unit (1.73 [1.49, 2.00]), attendance by a critical care physician (2.12 [1.33, 3.38]), older age (1.20 [1.12, 1.28] per 10-year increase), and use of intravenous steroids (1.16 [1.00, 1.34]), intravenous antibiotics (1.49 [1.22, 1.83]) and opioids (3.41 [2.95, 3.93]). Factors significantly associated with a lower risk of the composite outcome included female sex (0.70 [0.61, 0.80]), comorbid chronic obstructive pulmonary disease (0.69 [0.60, 0.78]), attendance by a family medicine physician (0.67 [0.48, 0.94]) or internal medicine physician (0.59 [0.46, 0.75]), and use of oral steroids (0.62 [0.51, 0.77]), statins (0.76 [0.67, 0.87]) and proton pump inhibitors (0.80 [0.70, 0.92]).In conclusion, patients with IPF are at risk of mortality during a hospital stay or readmission within 90 days, particularly those who receive mechanical ventilation.
住院治疗在特发性肺纤维化(IPF)患者中很常见,且与高死亡率相关。我们利用Premier医疗数据库的数据来确定在已批准抗纤维化药物时代IPF患者的住院死亡率以及与住院死亡率相关的因素。Premier医疗数据库是一个详细且具有广泛代表性的美国医院入院和出院数据库。使用包含国际疾病分类第9版和国际疾病分类第10版诊断代码以及计费数据的诊断算法,确定了2015年1月1日至2018年2月28日期间住院的IPF患者。使用逻辑回归分析患者、医院和治疗相关因素与以下复合结局之间的关联:在首次就诊期间死亡、在首次就诊期间但入院1天后进行肺移植、或在首次就诊后90天内再次入院期间死亡。该队列包括9667名住院的IPF患者。总共有1414名患者(14.6%)符合复合结局:1036名(10.7%)在首次就诊期间死亡,371名(3.8%)在90天内再次入院期间死亡;7名(0.1%)在入院1天后接受肺移植。与复合结局风险较高显著相关的因素包括机械通气(比值比6.41[95%置信区间:5.24,7.84])、入住重症监护病房(1.73[1.49,2.00])、由重症监护医生诊治(2.12[1.33,3.38])、年龄较大(每增加10岁为1.20[1.12,1.28]),以及使用静脉类固醇(1.16[裸奔,1.34])、静脉抗生素(1.49[1.22,1.83])和阿片类药物(3.41[2.95,3.93])。与复合结局风险较低显著相关的因素包括女性(0.70[0.61,0.80])、合并慢性阻塞性肺疾病(0.6q[0.60,0.78])、由家庭医生(0.67[0.48,0.94])或内科医生(0.59[0.46,0.75])诊治,以及使用口服类固醇(0.62[0.51,0.77])、他汀类药物(0.76[0.67,0.87])和质子泵抑制剂(0.80[0.70,0.92])。总之,IPF患者在住院期间或90天内再次入院时有死亡风险,尤其是那些接受机械通气的患者。